Glioma clinical trials in New York
28 studies for Glioma are looking for participants at sites in New York.
Cities in New York
- New York City26 studies
- Queens6 studies
- Staten Island4 studies
- New Rochelle4 studies
- Greenburgh4 studies
A Study of Mirdametinib in People With Central Nervous System Tumors
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07539441Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Northwell Health Center for Advanced Medicine - Brain Tumor Center, Lake Success
- Columbia University Irving Medical Center, New York
- Montefiore Medical Center, The Bronx
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07326566Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
- NYU Langone Health, New York
Recruiting
Ages 18 to 85 · All sexes · Updated Nov 12, 2026 · NCT06910306Observational Connectomics in Adults Undergoing Resection of WHO II-IV Glioma
- Lenox Hill Brain Tumor Center, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07927595Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
- NYU Langone Health, New York
- Columbia University Medical Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07703436A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
- NYU Langone Health, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07464925Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06810544SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- Memorial Sloan Kettering Cancer Center, New York
Recruiting
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT00870129Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, New York
- Research Site, New York
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Oct 5, 2026 · NCT05417594Glioma Developmental and HyperActive Ras Tumor (DHART) Board
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
- Memorial Sloan Kettering West Harrison (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT05489783Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- New York University, New York
RecruitingPhase 1
Ages 1 to 25 · All sexes · Updated Aug 18, 2026 · NCT04485559Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
- New York Presbyterian Hospital-Columbia University Medical Center, New York
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07486713A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
- Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05188508MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 1 to 26 · All sexes · Updated Jul 10, 2026 · NCT06712875Chronic CED of TPT for Recurrent Malignant Glioma
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 15, 2026 · NCT06666712A Study of 177Lu-PSMA-617 in People With Gliomas
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT07223034Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
- Lenox Hill Brain Tumor Center, New York
Recruiting
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT05979064Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- Lenox Hill Brain Tumor Center, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT05271240Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
- Lenox Hill Brain Tumor Center, New York
Recruiting
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT05954858A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- Roswell Park, Buffalo
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
- Memorial Sloan Kettering, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT06126744Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- Lenox Hill Brain Tumor Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT02800486DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
- Northwell Health, Lake Success
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 11, 2026 · NCT06504381FUS Etoposide for DMG
- Columbia University Irving Medical Center, New York
RecruitingPhase 1
Ages 4 to 21 · All sexes · Updated Jan 28, 2026 · NCT05762419Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
- NYU Langone Health, New York
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jan 2, 2026 · NCT06829173Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma
- University of Rochester, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT04543201From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.